OnCore Login

Return to Trial Database

HCRN-MM01-21

A Phase II Study of Daily Thalidomide, Oral Cytoxan and Prednisone for Relapsed or Refractory Multiple Myeloma

Status

Study Completed

Cancer Type(s)

Mutiple Myeloma

Study Contact

Publications

Final Report of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma
A Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma
  • R Abonour, K Ganjoo, C Fausel, C Yiannoutsos, BE Juliar, L Wood, G Smith, P Walker, L Cripe
Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma
  • A Suvannasankha, C Fausel, BE Juliar, CT Yiannoutsos, WB Fisher, RH Ansari, LL Wood, GG Smith, LD Cripe, R Abonour

Trial Locations

All sites in which the trial HCRN-MM01-21 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278